Details of the Drug Combination

General Information of Drug Combination (ID: DCKBJP1)

Drug Combination Name

Amonafide Topetecan

Indication

Disease Entry	Status	REF
Childhood T acute lymphoblastic leukemia	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Topetecan DMAE6LK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: CCRF-CEM

Zero Interaction Potency (ZIP) Score: 0.95

Bliss Independence Score: 1.25

Loewe Additivity Score: 3.02

LHighest Single Agent (HSA) Score: 4.01

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Amonafide

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[3]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCPT0DJ	HT29	Investigative	[1]
Adult acute myeloid leukemia	DCNIF9N	HL-60(TB)	Investigative	[1]
Anaplastic large cell lymphoma	DC1T41T	SR	Investigative	[1]
Astrocytoma	DCWIIPI	U251	Investigative	[1]
Lung adenocarcinoma	DCSYJZA	EKVX	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
4	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).